Mammary Gland HyperplasiaPhase 2NCT04767620
Clinical Trial of Ruxian Zengsheng No. 1 Decoction
A Phase 2 study testing Rugdenzengsheng No. 1 prescription in people with Mammary Gland Hyperplasia, run by Jiuda Zhao at 1 site in China.
Trial summary
A prospective, open, randomized, controlled phase II clinical study is planned to clarify the efficacy and related adverse reactions of Mammary Glandular Hyperplasia No. 1 Decoction in the treatment of liver-qi stagnation type breast hyperplasia, relieve the pain of patients with breast hyperplasia, and improve the… Read more about this study
- Who is it for?
- Ages 18 to 80 years, women only
- Conditions the study is for
- Mammary Gland Hyperplasia
- What is being tested?
- Rugdenzengsheng No. 1 prescription
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 137 participants
- Where
- 1 siteChina
- Study dates
- 1 Mar 2021to 31 Dec 2021
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Healthy women over 18 years of age;
- Patients who meet the diagnostic criteria for breast color Doppler ultrasound diagnosis of breast hyperplasia and the course of disease exceeds 3 months;
- Meet the syndrome differentiation criteria for liver-stagnation and qi stagnation (main symptoms are ① breast distension Pain and pain; ② breast pain and/or lumps are related to menstruation and mood changes; ③ irritability and irritability; ④ flank fullness. Secondary symptoms: ① the lumps are single, soft and tender; ② Young women; ③Irregular menstruation or dysmenorrhea; ④Pale red tongue, thin white or thin yellow coating, stringy pulse. With 3 main symptoms or 2 main symptoms + 2 secondary symptoms);
- breast color ultrasound, breast molybdenum Target, or breast MRI showed BI-RADS 2-3;
- NRS (0-10 pain rating) score ≥ 4 points on the most painful day before treatment, according to the score, the pain is divided into mild 3 points, moderate Grade 4-6 points, severe 7-10 points;
- Voluntarily participate in the clinical study and sign the informed consent form after the informed consent (patients voluntarily accept the study and sign the informed consent).
Who cannot join
- Patients with other breast diseases or other causes of breast pain (such as mastitis, breast cancer, etc.);
- Patients with severe cardiovascular and cerebrovascular diseases, liver, kidney, malignant tumors, blood system diseases, and Patients with mental illness;
- Patients who have been confirmed to have dysfunctional uterine bleeding, amenorrhea, polycystic ovary syndrome, menopausal syndrome and hyperprolactinemia before treatment, still need to regulate hormone levels for treatment;
- Patients diagnosed with hypercortisolism before treatment still need bromocriptine treatment;
- Menstrual period is more than 7 days, menopause and severe irregular menstrual cycle;
- ALT, AST, ALP, TBIL , GGT is higher than the upper limit of normal; or abnormal blood, urine, electrocardiogram and other examination items;
Show all 12Show fewer
- pregnant or breastfeeding women, or patients with pregnancy plans in the next six months;
- 1 before treatment Use Chinese or Western medicine to treat breast hyperplasia (including painkillers, topical drugs, acupuncture, etc.) within the month and during the treatment period, and use hormonal drugs (except for long-term use), and oral contraceptives within six months;
- People who are known to be allergic to the ingredients of the test drug prescription;
- Past alcohol or drug abuse history;
- Patients who participated in other clinical studies within 3 months before enrollment;
- According to the judgment of the researchers, there are other diseases Or circumstances will reduce the possibility of enrollment or complicate enrollment. For example, frequent changes in the work environment may cause loss to follow-up, and patients with mental and behavioral disorders, or the inability to sign informed consent.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Qinghai University Affiliated Hospital
Qinghai, Xining, Qinghai, 810000
Zhao Jiuda, MD, 13327661976, jiudazhao@126.com
About this study
Official title: A Prospective, Open, Randomized, Controlled Phase Ⅱ Clinical Study of Ruxian Zengsheng No. 1 Decoction in Treating Liver-stagnation and Qi-stagnation Hyperplasia of Breast
A prospective, open, randomized, controlled phase II clinical study is planned to clarify the efficacy and related adverse reactions of Mammary Glandular Hyperplasia No. 1 Decoction in the treatment of liver-qi stagnation type breast hyperplasia, relieve the pain of patients with breast hyperplasia, and improve the quality of life of patients.
Read the detailed description
- This study is a prospective, open, randomized, controlled Phase II clinical study. Strictly follow the design requirements of the clinical research, randomly enroll patients, control each link of the study with high quality, and obtain objective research results to improve the evidence-based medicine evidence of the breast hyperplasia treatment of liver-stagnation and qi stagnation type breast hyperplasia with Rugongshengsheng No.1 prescription;
- Recruiting 137 patients with liver-stagnation and qi stagnation type breast hyperplasia through the Breast Center Clinic of the Affiliated Hospital of Qinghai University (see the inclusion criteria for details) (see the research plan for the specific calculation method), and randomly divided into 91 cases according to the 2:1 random number method Group, 46 cases of control group. The research group was treated with No.1 Rugdenzengsheng prescription for a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The control group was given observation treatment and follow-up in outpatient clinic. All patients will be followed up by telephone or outpatient by a dedicated person, and the results of the follow-up will be recorded objectively;
- Specific treatment plan: The study group was treated with Mammary gland Hyperplasia No. 1 orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, Beibuihu 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control;
- All patients will be followed up by telephone or on-site within one week after treatment. The evaluation criteria are detailed in the attached table. The curative effect evaluation standard of hyperplasia of mammary glands is mainly through the scoring method. The analgesic curative effect standard (NRS score on the most painful day): clinical recovery: the pain disappears completely; marked effect: the pain is significantly reduced, only occasional pain or only slight tenderness; effective : Pain is reduced or tenderness is reduced; Ineffective: Pain remains unchanged or worsened. In addition, collect clinical pathological data of patients, such as age, gender, reproductive history, menstrual history, family history, breastfeeding history, etc.;
- Secondary efficacy indicators: safety evaluation, safety endpoints include the incidence of adverse events and adverse reactions, liver function, renal function and urine routine laboratory examinations before and after treatment;
- Apply for ethical review by the ethics committee of the Affiliated Hospital of Qinghai University, and conduct research in strict accordance with the ethical requirements of the ethics committee of the Affiliated Hospital of Qinghai University.
- Conditions
- Mammary Gland Hyperplasia
- Being tested
- Rugdenzengsheng No. 1 prescription
- Keywords
- Mammary gland hyperplasia, Liver Qi stagnation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rugdenzengsheng No. 1 prescriptionDrug
Also called non
The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
| Study group | Role | What they receive |
|---|---|---|
| study groups | Experimental | The study group was treated with Rugdenzengsheng No. 1 prescription for 2 courses. Receives: Drug: Rugdenzengsheng No. 1 prescription |
| control groups | No intervention | The control group was treated with observational treatment and follow-up in outpatient clinic. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Relief Rate of Mammary Gland Pain
To clarify the effectiveness of Rugshengsheng No.1 Recipe in the Affiliated Hospital of Qinghai University in reducing the pain of patients with liver-stagnation and qi stagnation type breast hyperplasia, as well as related adverse side effects, and provide reliable clinical evidence for further clinical promotion
Measured: 12 weeks
Secondary outcomes (2)
Relief time of breast pain
Related Adverse Reactions of Rugongshengsheng No.1 Prescription
Measured: 12 weeks
Related adverse reactions
Statistic about the related adverse reactions of patients after taking the No.1 Recipe for Mammary Gland Growth, the degree and severity of the adverse reactions
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2021
- Study start1 Mar 2021 (estimated)
- Primary completion31 Dec 2021 (estimated)
- Study completion31 Dec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mammary Gland HyperplasiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- non
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 137 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jiuda Zhao
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Jiuda Zhao, Affiliated Hospital of Qinghai University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04767620
- Sponsor's protocol ID
- AHQU-2021002
- Status last verified
- Feb 2021
- First submitted
- 9 Feb 2021
- Last updated
- 23 Feb 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Open, Randomized, Controlled Phase Ⅱ Clinical Study of Ruxian Zengsheng No. 1 Decoction in Treating Liver-stagnation and Qi-stagnation Hyperplasia of Breast
- ClinicalTrials.gov ID
- NCT04767620
- Acronym / sponsor ID
- AHQU-2021002
- Conditions
- Mammary Gland Hyperplasia
- Keywords
- Mammary gland hyperplasia, Liver Qi stagnation
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 137 participants (estimated)
- Lead sponsor
- Jiuda ZhaoUniversity, hospital or other
- Study start
- 1 Mar 2021 (estimated)
- Primary completion
- 31 Dec 2021 (estimated)
- Study completion
- 31 Dec 2021 (estimated)
- First posted
- 23 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A prospective, open, randomized, controlled phase II clinical study is planned to clarify the efficacy and related adverse reactions of Mammary Glandular Hyperplasia No. 1 Decoction in the treatment of liver-qi stagnation type breast hyperplasia, relieve the pain of patients with breast hyperplasia, and improve the quality of life of patients.
Detailed description
- This study is a prospective, open, randomized, controlled Phase II clinical study. Strictly follow the design requirements of the clinical research, randomly enroll patients, control each link of the study with high quality, and obtain objective research results to improve the evidence-based medicine evidence of the breast hyperplasia treatment of liver-stagnation and qi stagnation type breast hyperplasia with Rugongshengsheng No.1 prescription;
- Recruiting 137 patients with liver-stagnation and qi stagnation type breast hyperplasia through the Breast Center Clinic of the Affiliated Hospital of Qinghai University (see the inclusion criteria for details) (see the research plan for the specific calculation method), and randomly divided into 91 cases according to the 2:1 random number method Group, 46 cases of control group. The research group was treated with No.1 Rugdenzengsheng prescription for a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The control group was given observation treatment and follow-up in outpatient clinic. All patients will be followed up by telephone or outpatient by a dedicated person, and the results of the follow-up will be recorded objectively;
- Specific treatment plan: The study group was treated with Mammary gland Hyperplasia No. 1 orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, Beibuihu 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control;
- All patients will be followed up by telephone or on-site within one week after treatment. The evaluation criteria are detailed in the attached table. The curative effect evaluation standard of hyperplasia of mammary glands is mainly through the scoring method. The analgesic curative effect standard (NRS score on the most painful day): clinical recovery: the pain disappears completely; marked effect: the pain is significantly reduced, only occasional pain or only slight tenderness; effective : Pain is reduced or tenderness is reduced; Ineffective: Pain remains unchanged or worsened. In addition, collect clinical pathological data of patients, such as age, gender, reproductive history, menstrual history, family history, breastfeeding history, etc.;
- Secondary efficacy indicators: safety evaluation, safety endpoints include the incidence of adverse events and adverse reactions, liver function, renal function and urine routine laboratory examinations before and after treatment;
- Apply for ethical review by the ethics committee of the Affiliated Hospital of Qinghai University, and conduct research in strict accordance with the ethical requirements of the ethics committee of the Affiliated Hospital of Qinghai University.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- non
| Arm | Type | Receives |
|---|---|---|
| study groups | Experimental | Drug: Rugdenzengsheng No. 1 prescriptionThe study group was treated with Rugdenzengsheng No. 1 prescription for 2 courses. |
| control groups | No intervention | –The control group was treated with observational treatment and follow-up in outpatient clinic. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Healthy women over 18 years of age;
- Patients who meet the diagnostic criteria for breast color Doppler ultrasound diagnosis of breast hyperplasia and the course of disease exceeds 3 months;
- Meet the syndrome differentiation criteria for liver-stagnation and qi stagnation (main symptoms are ① breast distension Pain and pain; ② breast pain and/or lumps are related to menstruation and mood changes; ③ irritability and irritability; ④ flank fullness. Secondary symptoms: ① the lumps are single, soft and tender; ② Young women; ③Irregular menstruation or dysmenorrhea; ④Pale red tongue, thin white or thin yellow coating, stringy pulse. With 3 main symptoms or 2 main symptoms + 2 secondary symptoms);
- breast color ultrasound, breast molybdenum Target, or breast MRI showed BI-RADS 2-3;
- NRS (0-10 pain rating) score ≥ 4 points on the most painful day before treatment, according to the score, the pain is divided into mild 3 points, moderate Grade 4-6 points, severe 7-10 points;
Key exclusion criteria (12 listed)
- Patients with other breast diseases or other causes of breast pain (such as mastitis, breast cancer, etc.);
- Patients with severe cardiovascular and cerebrovascular diseases, liver, kidney, malignant tumors, blood system diseases, and Patients with mental illness;
- Patients who have been confirmed to have dysfunctional uterine bleeding, amenorrhea, polycystic ovary syndrome, menopausal syndrome and hyperprolactinemia before treatment, still need to regulate hormone levels for treatment;
- Patients diagnosed with hypercortisolism before treatment still need bromocriptine treatment;
- Menstrual period is more than 7 days, menopause and severe irregular menstrual cycle;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rugdenzengsheng No. 1 prescriptionAlso: nonThe study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control. | Drug | study groups |
Primary outcome
Relief Rate of Mammary Gland Pain
Time frame: 12 weeks
To clarify the effectiveness of Rugshengsheng No.1 Recipe in the Affiliated Hospital of Qinghai University in reducing the pain of patients with liver-stagnation and qi stagnation type breast hyperplasia, as well as related adverse side effects, and provide reliable clinical evidence for further clinical promotion
2 secondary outcomes
Relief time of breast pain
Time frame: 12 weeks
Related adverse reactions
Time frame: 12 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2021.
- Individual participant dataSharing planned: No
Related trials for Mammary Gland Hyperplasia
Active, not recruitingPhase 3
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ
RecruitingObservational study
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Cancer Risk, Cancer Predisposition Syndrome
RecruitingPhase 2
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Breast Atypical Hyperplasia, Breast Carcinoma
RecruitingPhase 2
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
RecruitingPhase 2
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
Breast Atypical Hyperplasia, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Rugdenzengsheng No. 1 prescription in people with Mammary Gland Hyperplasia, run by Jiuda Zhao at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Relief Rate of Mammary Gland Pain (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2021.